Company profile
PUMA BIOTECHNOLOGY, INC.
NASDAQ:PBYIBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NERATINIB | phase2 | — | 3 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (36)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00398567 | phase1_2 | completed | 2007-04-04 | 2009-07-31 | Puma Biotechnology, Inc. | A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer |
| NCT00445458 | phase1_2 | completed | 2007-09-11 | 2011-05-01 | Puma Biotechnology, Inc. | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer |
| NCT01128842 | phase1 | completed | 2010-04-01 | 2011-03-01 | Puma Biotechnology, Inc. | A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor |
| NCT00397046 | phase1 | completed | 2006-11-01 | 2009-03-01 | Puma Biotechnology, Inc. | A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors |
| NCT07465757 | phase2 | not_yet_recruiting | 2026-09-30 | 2028-03-31 | Puma Biotechnology, Inc. | A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 208051 | NDA | PUMA BIOTECHNOLOGY INC | ||||
Loading… | ||||||